Evidence map›Paper›PMID 32169158›Full record

ArticleThe lancet. HIV2020

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.

Ravindra Kumar Gupta, Dimitra Peppa, Alison L Hill, Cristina Gálvez, Maria Salgado, Matthew Pace, Laura E McCoy, Sarah A Griffith, John Thornhill, Aljawharah Alrubayyi and 10 more

Registry-linked trialOpen access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The lancet. HIV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06626555 (Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection), which is not on this map. Cited by 138 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 1 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06626555 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection

TypeinterventionalSponsorUniversity College, LondonRan2024 to 2026Enrolled36ConditionsHIVArmsLetermovir
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  10. Review
  11. Article
  12. HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression?Microbiology and molecular biology reviews : MMBR · 2025
    Review
  13. Review
  14. The STAT Signaling Pathway in HIV-1 Infection: Roles and Dysregulation.International journal of molecular sciences · 2025
    Review
  15. CRISPR/Cas9 for achieving postintervention HIV control.Current opinion in HIV and AIDS · 2025
    Review
  16. Review
  17. Review
  18. HIV Cure: How Far We Have Come?Indian journal of microbiology · 2025
    Review
  19. Engineering of CD8mBio · 2025
    Article
  20. Review

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 5 countries.

Ravindra Kumar GuptaDepartment of Medicine, University of Cambridge, Cambridge, UK; Africa Health Research Institute, Durban, South Africa. Electronic address: rkg20@cam.ac.uk.
Dimitra PeppaNuffield Department of Medicine, University of Oxford, Oxford, UK; Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK.
Alison L HillDepartment for Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA.
Cristina GálvezIrsiCaixa AIDS Research Institute, Badalona, Spain; Autonomous University of Barcelona, Cerdanyola del Vallès, Spain.
Maria SalgadoIrsiCaixa AIDS Research Institute, Badalona, Spain.
Matthew PaceNuffield Department of Medicine, University of Oxford, Oxford, UK.
Laura E McCoyDivision of Infection and Immunity, University College London (UCL), London, UK.
Sarah A GriffithDivision of Infection and Immunity, University College London (UCL), London, UK.
John ThornhillImperial College London, London, UK.
Aljawharah AlrubayyiNuffield Department of Medicine, University of Oxford, Oxford, UK.
Laura E P HuyveneersDepartment of Medical Microbiology, University Medical Center, Utrecht, Netherlands.
Eleni NastouliDivision of Infection and Immunity, University College London (UCL), London, UK; Department of Virology, UCL Hospitals, London, UK; Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK.
Paul GrantDepartment of Virology, UCL Hospitals, London, UK.
Simon G EdwardsMortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
Andrew J InnesImperial College London, London, UK; Imperial College NHS Healthcare Trust, Hammersmith Hospital, London, UK.
John FraterNuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford National Institute for Health Research Biomedical Research Centre, Oxford, UK.
Monique NijhuisDepartment of Medical Microbiology, University Medical Center, Utrecht, Netherlands.
Anne Marie J WensingDepartment of Medical Microbiology, University Medical Center, Utrecht, Netherlands.
Javier Martinez-PicadoIrsiCaixa AIDS Research Institute, Badalona, Spain; University of Vic - Central University of Catalonia, Vic, Spain; Catalan Institution for Research and Advanced Studies, Barcelona, Spain.
Eduardo OlavarriaImperial College London, London, UK; Mortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
University College London · GBUniversity Medical Center Utrecht · NLImperial College London · GBIrsiCaixa · ESUniversity of Oxford · GBGreat Ormond Street Hospital · GBHarvard University · USImperial College Healthcare NHS Trust · GBMortimer Market Centre · GBNational Institute for Health Research · GBUniversitat de Vic - Universitat Central de Catalunya · ESUniversity College Hospital · GBUniversity of Cambridge · GB

Funding

Medical Research Council MR/L006588/1Medical Research Council MR/M008614/2Medical Research Council MRM008614/2Medical Research Council MR/N001265/1Medical Research Council MR/R008698/1Wellcome Trust WT108082AIA
6 · The paper itself

Abstract

backgroundThe London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR5 (CCR5Δ32/Δ32); remission was reported at 18 months after analytical treatment interruption (ATI). Here, we present longer term data for this patient (up to 30 months after ATI), including sampling from diverse HIV-1 reservoir sites.

methodsWe used ultrasensitive viral load assays of plasma, semen, and cerebrospinal fluid (CSF) samples to detect HIV-1 RNA. In gut biopsy samples and lymph-node tissue, cell-copy number and total HIV-1 DNA levels were quantified in multiple replicates, using droplet digital PCR (ddPCR) and quantitative real-time PCR. We also analysed the presence of intact proviral DNA using multiplex ddPCR targeting the packaging signal (ψ) and envelope (env). We did intracellular cytokine staining to measure HIV-1-specific T-cell responses. We used low-sensitive and low-avidity antibody assays to measure the humoral response to HIV-1. We predicted the probability of rebound using a mathematical model and inference approach.

findingsHIV-1 viral load in plasma remained undetectable in the London patient up to 30 months (last tested on March 4, 2020), using an assay with a detection limit of 1 copy per mL. The patient's CD4 count was 430 cells per μL (23·5% of total T cells) at 28 months. A very low-level positive signal for HIV-1 DNA was recorded in peripheral CD4 memory cells at 28 months. The viral load in semen was undetectable in both plasma (lower limit of detection [LLD] <12 copies per mL) and cells (LLD 10 copies per 10

interpretationThe London patient has been in HIV-1 remission for 30 months with no detectable replication-competent virus in blood, CSF, intestinal tissue, or lymphoid tissue. Donor chimerism has been maintained at 99% in peripheral T cells. We propose that these findings represent HIV-1 cure.

fundingWellcome Trust and amfAR (American Foundation for AIDS Research).

Indexed as

Hematopoietic Stem Cell TransplantationHIV-1AllograftsFollow-Up StudiesHIV InfectionsHumansMaleReceptors, CCR5SemenTreatment OutcomeViral LoadCCR5 protein, humanReceptors, CCR5

Identifiers

PMID32169158
PMCPMC7606918
OpenAlexW3010724614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.